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In the business world, the above heading is an expres-
sion indicating a business’ return to basic issues after
they have been forgotten, or they have faded out for
some reason. Considering recent observations, this ex-
pression is applicable to the expected tightening of by
food supervision in order to root out illegal and mis-
leading information from the food market.
It is a well-known fact that the health market fares
well. The border zone between medicinal and food
products is an excellent example of this. With certain
kinds of imagery and misleading information, the hu-
man mind is sensitised to desire a long and healthy life.
Unfortunately, this is good business for some people. In
developed countries, there is, however, a desire to pre-
vent deception with foodstuffs.
Finnish food legislation is up to date in this aspect.
The purpose of the food legislation is, amongst other
things, to ensure the truthful and sufficient dissemina-
tion of information on food, and to prevent misleading
information. The assertion or inference that any food-
stuff owns prophylactic, therapeutic or healing attribut-
es for human illnesses is particularly prohibited. Human
food is meant to be food and not medicine.
Products that are more problematic than normal
foods include the so-called nutritional supplements,
which may be reminiscent of medicines due to their
form, such as tablets, capsules, pills, powders, liquids,
and other dosage forms. Their purpose is to comple-
ment the diet, or affect the nutritional or physiological
functions of the human body in some manner or anoth-
er. According to the decree issued by the Ministry of
Trade and Industry in August, any claims or inferences
to the effect that a nutritional supplement owns prophy-
lactic, therapeutic or healing attributes for human illness
are prohibited on packaging, in brochures, advertise-
ments, or in any other medium. Can it be put more
clearly? 
However, as is experienced in life in general, some
kinds of foodstuffs and nutritional supplements will be
foisted on the consumer, and the main  promotional
message of such goods will go against the aforemen-
tioned regulation. Consumers and patients are confused,
but so are the traders, too. One can easily get the im-
pression that there are two sets of regulations in the
health market.
In Finland, according to food legislation, the admin-
istration of control belongs to the National Food
Agency (EVI). The  regional administrations and munic-
ipalities play a central role in the practicalities of the
control. The nationwide food control program being
prepared by EVI for implementation in 2004 covers a
range of control projects. One of these projects, named
the “Forbidden Health Assertions”, has commenced al-
ready this year. The aim for the year 2004 is to carry
out targeted strikes against health assertions in co-oper-
ation with officials of the  regional authorities and mu-
nicipalities. This enterprise is highly welcome. The de-
ception of consumers and patients should be stopped.
In a category of their own are functional foods or
foods beneficial for the health, for which there are nei-
ther definitions, evidence-based criteria nor  regulatory
system in the Finnish national legislation or in that of
the EU. As long as the  manufacturers or the marketers
are allowed to decide for themselves whether a product
is functional or beneficial to human health, then the










Atrial fibrillation (AF) is the most
common type of cardiac arrhythmia
that a physician will come across in
his/her practice; its prevalence in the
oldest patient groups is nearly 10%.
AF is usually not an acute threat to
the patient’s life, but the subsequent
symptoms may disable the patient.
AF is also associated with a consid-
erable risk of thrombo-embolic
events, especially of a cerebral in-
farct, and it may exacerbate cardiac
insufficiency in the patient (1). The
results of long-term prophylactic
treatment of AF are poor. In a one-
year follow-up, AF recurs in
60–80% of the patients treated.
Among the drugs in the Vaughan-
Williams classification group those
most often used in AF prophylaxis
belong to the groups I A, I C, II and
III (Table). The majority of studies
on AF have been carried out with
quite small samples of patients and
there are no satisfactory compara-
tive studies on the efficacy of vari-
ous prophylactic drugs. According
to the recommendations of
AHA/ACC/ESC, prophylaxis of AF
is justified in patients with severe
symptoms. The patients most at
risk, such as post-myocardial infarc-
tion patients, should nevertheless
not be treated with proarrhythmo-
genic drugs (2).
Drug-free treatment
AF patients often ask whether their
manner of life can affect the recur-
rence of AF. Even though all heart
patients can be counselled to avoid
smoking and to follow a correct di-
et, no answer supported by studies
can be given to this question. A
hangover may trigger AF in some
patients, and the patients can natu-
rally be advised to avoid hangovers.
Beta blocking agents
Beta-blockers are the drugs of choice
in the prophylaxis of AF. They are
usually well tolerated and associated
with a positive prognostic effect in
patients with hypertension or is-
chaemic heart disease. Beta-blockers
are not, however, notably effective
in the prevention of AF. In a rela-
tively extensive study, metoprolol
was shown to reduce the occurrence
of AF in only less than 20% of the
patients during a 6-month follow-up
(3). Comparative studies of the pro-
phylactic effect of different beta-
blockers in AF have not been con-
ducted, and consequently, the bene-
fit of beta1-selectivity, combined al-
pha-beta-blocking, the ISA effect, or
various fat/water solubility cannot
be shown, but it is recommended
that a couple of different beta block-
ing agents be tried before introduc-
ing other drugs.
Sotalol
It is easy to consider sotalol merely
as a beta blocking agent, but ac-
cording to the classification of
Vaughan-Williams it is, in fact, a
group III drug which prolongs the
repolarisation of the cardiac cells
and consequently the QT interval. 
A long QT interval exposes the pa-
tient to a life-threatening torsade de
pointes tachycardia. According to
the adverse reactions register main-
tained by the WHO, sotalol is clear-
ly the most important one of the
torsade de pointes tachycardia-in-
ducing drugs. Since sotalol, accord-
ing to studies, is no more effective
than metoprolol or bisoprolol in the
prophylaxis of AF, I do not think so-
talol should be used in the prophy-
laxis of AF (4).
Flecainide
Flecainide, the I C group drug, is af-
ter beta-blockers the most common-
ly used drug in the treatment of AF
in Finland. Its efficacy is comparable
to that of other I A and I C groups
of drugs, i.e. a one-year follow-up
shows a recurrence of AF in about
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Prophylaxis of atrial fibrillation is probably the most common indication for the use of antiar-
rhythmic drugs. For the prophylaxis of atrial fibrillation, a physician may try beta-blockers, or, in
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40–50% of the patients treated (5).
Due to its proarrhythmogenic prop-
erties, a reliable exclusion of struc-
tural heart defect, ischaemic heart
disease, past history of cardiac in-
farct and cardiac failure in patients
should be made prior to the use of
flecainide. It is recommended that
the flecainide therapy be started by
a specialist and that, prior to the
start of medication, the patient
should undergo a cardiac ultrasound
examination, including after careful
consideration a clinical exercise test.
It is recommended that after the in-
troduction of the medication a rest-
ing ECG be checked at least and
preferably also a clinical exercise
test be performed to ensure that the
QRS complex is not prolonged by
more than 40–50%. A congenital
slow metabolism of flecainide is
found in 10% of patients and even
small doses can cause proarrhyth-
mogenic blood concentration. Fle-
cainide should always be used in
combination with a beta-blocker for
additional efficacy and safety.
Amiodarone
Amiodarone is the most effective
and best known drug used in the
prophylaxis of AF. In a 16-month
follow-up, AF recurred in 35% of
the patients treated, whereas in pa-
tients on propafenone or sotalol
therapy, the recurrence was 64%.
Adverse reactions leading to inter-
ruption of treatment were somewhat
more frequent with amiodarone,
however (6). Amiodarone can also
safely be used in patients with is-
chaemic heart disease or cardiac in-
sufficiency, and it does not expose
the patients to life-threatening car-
diac arrhythmias. However, other
significant adverse effects are associ-
ated with the use of amiodarone, the
most dreaded one of which is an
amiodarone-induced pulmonary re-
action. Amiodarone can also cause
hyperthyreosis or liver damage. Pri-
or to the introduction of amiodar-
one that the patient’s lung diffusion
capacity should be established  as
well as liver and thyroid values.
These values should also be moni-
tored at intervals of 3–6 months for
a year at first, and annually there-
after.
ACE inhibitors and angiotensin II
antagonists
In recent years, the possibility of us-
ing angiotensin-converting enzyme
inhibitors and angiotensin II recep-
tor blockers in the prophylaxis of
AF has emerged. In a TRACE study,
prophylaxis with ACE introduced
following a myocardial infarction
reduced the frequency of AF by over
50% compared with a placebo (7).
When amiodarone was combined
Medicinal  substances used in the prophylaxis  of  atr ial  f ibr i l lat ion.  The recommended drugs are indicated
in bold.  
Medicinal substance Advantages Disadvantages Important 
Beta-blockers Safe,  with a  posit ive Poor  ef f icacy
prognostic  ef fect  
F lecainide More ef fect ive than Not  for  pat ients  with Severe cardiac ar
beta blocking agents another  heart  disease arrhythmias even at  
smal l  concentrat ions
in 10% of  pat ients  
Amiodarone The most  ef fect ive one Adverse react ions:  Monitoring of diffusion
of  the known prophylact ics amiodarone- induced capacity,  l iver  and
Other  heart  diseases do pulmonary react ion, thyroid values 
not  prevent  use hyperthyreosis,  
l iver  damage 
ACE inhibitors  and S a f e
angiotensin I I   Another  useful  prof i le   Insuff ic ient  proof
antagonists of  act ion of  ef f icacy so far  
Digitalis Does not prevent recurrences 
of atrial fibrillation 
Quinidine Increased mortality 
Disopyramide Adverse reactions 
in 26% of patients 
Propafenone Not for patients with 
another heart disease 
Verapamil, Inhibition of the atrial Importance in prophylaxis 
diltiazem remodelling phenomenon  of atrial fibrillation unknown
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with an angiotensin II antagonist,
irbesartan, the sinus rhythm was re-
tained in 83% of the patients during
a 9-month follow-up, whereas the
sinus rhythm was retained in 52%
of the patients on amiodarone thera-
py alone (8). ACE inhibitors and an-
giotensin II antagonists are consid-
ered to inhibit the structural changes
of the atria, primarily the fibrotisa-
tion. In animal studies it has also
been found to prevent electrophysio-
logical changes, which may be a re-
sult of the prevention of structural
changes (9). So far, no randomised
studies have been made on the effi-
cacy of ACE inhibitors or angio-
tensin II antagonists in the preven-
tion of AF, but they can already be
recommended in patients with hy-
pertension, cardiac insufficiency,
mild mitral insufficiency or in pa-
tients who exhibit some atheroscle-
rosis.
Other drugs
Among the drugs of the I A group,
quinidine has previously been exten-
sively used in the prophylaxis of AF.
Compared with a placebo, however,
quinidine causes a three-fold in-
crease in patient mortality, and con-
sequently its use should be avoided
(10). Disopyramide and propafen-
one have also been used in the pro-
phylaxis of AF, but their efficacy is
not superior to that of any other
prophylactic agents and their use is
associated with an array of adverse
reactions and restrictions. Digitalis
does not prevent the recurrence of
AF, but it can be used together with
a beta-blocker to reduce the pulse
level in that condition. Digitalis is
especially useful in patients with car-
diac insufficiency. Calcium channel
blockers have been found to have a
positive effect with respect to the
electrical changes caused by AF;
their benefit in the prophylaxis of
AF has not been adequately studied,
however. Recurrence of AF can be
prevented by dofetilide, but the drug
is not yet available in Finland. In the
future, azimilide and dronedarone
may also be used in the prophylaxis
of AF (11).
The adoption of pulse control
and invasive treatment
We often come across a situation
where, despite several trials with
prophylactic agents, the patient con-
tinues having recurrent AF events re-
quiring cardioversion. A discussion
with the patient is recommended in
this case to see if AF can be tolerat-
ed together with adequate pulse rate
control by taking a beta blocker and
digitalis as necessary. According to
an AFFIRM study, in the more el-
derly patients at least this practice is
even safer than repeated cardiover-
sions (12). It is recommended that
certain, carefully chosen patients
should also consult a cardiologist in
view of the possibility of ablation
therapy for their AF.
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Carpal tunnel syndrome is charac-
terised by compression of the medi-
an nerve in the carpal tunnel of the
wrist. The main symptoms include
numbness of the thumb and the in-
dex and middle fingers and a tin-
gling sensation and pain especially
at night. The syndrome is more
common in women than in men.
Gynaecologists are familiar with the
condition because it is seen fairly of-
ten towards the end of pregnancy
and spontaneously disappears after
delivery. According to the literature,
hormone therapy during menopause,
especially oestrogen-induced fluid
accumulation in the tissues, is con-
sidered one of the risk factors for
carpal tunnel syndrome (1, 2).
My first patient was an other-
wise healthy female, except for mi-
graine which had troubled her for
years during her menstrual periods.
Due to menopausal symptoms, a
cyclic therapy with oestrogen-
progestogen was introduced at the
age of 50. The symptoms disap-
peared, but due to migraine associ-
ated with withdrawal bleeding,
treatment with tibolone which does
not induce bleeding was suggested
to the patient when she was 54.
With the customary dose of 1 tablet
a day, menopausal symptoms and
migraine were totally avoided. With-
in a couple of months, severe pains
started occurring in the hands, espe-
cially at night, to the extent that the
patient had been admitted for exam-
inations on the suspicion of rheuma-
tism. Weight increase was not con-
firmed, but she felt swelling in the
fingers. Clinically, no swelling was
found. As carpal tunnel syndrome
appeared likely, tibolone therapy
was withdrawn and the patient was
transferred to a continuous com-
bined therapy of oestrogen and
progestogen at a fixed dose. Pains in
the hands disappeared immediately,
but due to bleeding problems, ti-
bolone therapy was tried once more,
this time by halving the daily dose.
Severe symptoms in the hands fol-
lowed again, and tibolone therapy
had to be stopped, after which the
patient again became symptom-free.
Subsequently, an appropriate thera-
py was found by using the above-
mentioned continuous combined
therapy, without bleeding or other
problems. I should perhaps mention
that the outcome of the examina-
tions for rheumatism was negative.
Due to hot flushes, my second
patient was started on cyclic oestro-
gen-progestogen therapy so that
withdrawal bleeding occurred every
three months. Since the bleeding was
always associated with migraine, ti-
bolone was introduced when the pa-
tient reached 61 years. Menopausal
symptoms did not recur, and the pa-
tient had no migraine. Within a cou-
ple of months the patient’s weight
had nevertheless increased by 5 kg.
There was no swelling, clinically or
subjectively. Due to a severe tingling
sensation and numbness in the
hands, however, the patient’s night-
time sleep was disturbed. Based on
the experience gained from the treat-
ment of the first patient, tibolone
was withdrawn, and symptoms in
the hands thereupon disappeared. A
smaller dose of tibolone was not
tried in this patient, especially as the
appropriate treatment for her, too,
was found to be the continuous
combined therapy of oestrogen and
progestogen at a fixed dose.
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Consumers are, to an increasing de-
gree, searching through the Internet
for medical information. Illness re-
lated marketing is one way of dis-
seminating medical information. 
Illness related marketing refers
to the information on offer to the
consumer regarding illnesses/symp-
toms and associated means of treat-
ment. The aim should not be the
marketing of a drug preparation,
but creating awareness of an illness
and supplying information on the
use of medicinal preparation. Infor-
mation should be given even-hand-
edly on all treatment alternatives.
The initiator of illness related
marketing is usually a pharmaceuti-
cal company, but it may also be
some other commercial enterprise,
e.g. a health centre or a pharmacy.
The Internet is the most popular
medium for illness related market-
ing. Several pharmaceutical compa-
nies maintain web pages with infor-
mation on the illnesses treated with
the company’s products, symptoms
of the illnesses and various drug and
alternative therapies.
The aim of a survey carried out
in the spring of 2003 was to outline
the Finnish consumers’ search for in-
formation on the Internet pages of
illness related marketing. The pur-
pose was to establish what kind of
information consumers are looking
for on the pages and what informa-
tion they believe they do receive,
whether the consumers are satisfied
with the information received and
what follow-up measures they were
encouraged to pursue. 
The material was made up of a
28-day review of seven different web
pages of illness related marketing
maintained by pharmaceutical com-
panies. The illnesses involved on the
web pages included migraine, erec-
tion disturbances, diabetes, noctur-
nal enuresis, pain and hair loss in
men.
The key subjects in the survey
consisted of consumers who used
pages of illness related marketing as
their source of information. The
sample form was single random
sampling. The selected persons were
those who completed all the queries
in the review. The questionnaire ap-
peared on the screen when the con-
sumer logged on to the Internet
pages. A total of 672 replies were
received.
Results
Those selected in the sample corre-
sponded to the Internet user profile
of medical information established
in international surveys. The respon-
dents were mainly women, highly
educated, living in towns of over
50,000 inhabitants and aged under
50. Among the total group of re-
spondents the women were on aver-
age better educated than the men,
whereas the men were older than
the women. This was due to the ar-
eas of indication within which the
review was done: men were the pre-
dominant sex only on the web pages
involving erection disturbances and
loss of hair.
The respondents were mainly
seeking information on medical
treatment, causes of illnesses and
symptoms of illnesses (Fig. 1). 
When respondents were asked
how they valued the importance of
various elements of medical treat-
ment (scale: 1 not at all important –
5 very important), the highest scores
concerned the effects of medical
treatment (4.59) and the adverse re-
actions caused by medication (4.41).
The lowest score obtained con-
cerned the costs of medical treat-
ment (3.84). The area in between
was covered by various alternative
prescription drugs, interactions of
various medications and alternative
OTC preparations. The standard de-
viation for each alternative was
small.
The majority of respondents
(60%) were satisfied with the infor-
mation they received from the web
pages of illness related marketing.
The respondents who were not satis-
fied with the information they re-
ceived (40%) were asked about the
areas on which they would like to
have more information. More infor-
mation was wanted mainly on med-
ical treatment (54%), alternative
treatments (50%) and causes of ill-
ness (48%). More information re-
garding medical treatment was
wanted mainly on the alternatives
among OTC preparations (70%), ef-
fects of medical treatment (65%)
and various alternatives among pre-
scription drugs (64%). 
The respondents reported a doc-
tor, and other Internet pages, as
their most important additional
sources of information (Fig. 2).
27% of the respondents reported
that they would contact a doctor as
a follow-up measure. Equally 27%
were not able to tell whether they
would seek follow-up treatment or
not. 19% reported being under ade-
quately good treatment as it was.
42% of the respondents reported
that the information they had re-
ceived on the Internet pages had no
effect on their decision about fol-
low-up treatment measures, 32%
were unable to say whether the
pages had any effect or not, and
26% replied that they did have an
effect. The respondents’ opinion on
the effect of the pages had a statisti-
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cally important effect on the deci-
sion about follow-up treatment.
Conclusions
The increased need for information
among consumers on their illnesses
and associated treatment is not a
phenomenon independent of the sur-
rounding community; rather is it
part of an overall change leading to-
wards the information society. Fin-
land can be considered an ”informa-
tion society No 1” for various dif-
ferent reasons, and consumers in
Finland have excellent opportunities
to receive medical information from
various sources. One of the most
used and debated new sources is the
Internet.
According to international sur-
veys, medical information is the sec-
ond most often searched subject
area on the Internet (1). At least two
percent of the web pages discuss is-
sues associated with health (2). An
average of 40% of Internet users
have at some point sought medical
information on the Net (3). It is cer-
tain that both the demand for and
the supply of medical information
are constantly increasing (4).
Consumers appreciate the Inter-
net as a source of medical informa-
tion because information can be
searched for at times most suited to
them (5). As a source of informa-
tion, the Internet is varied and
searches can be made anonymously;
it is common to use the Internet for
searches associated especially with
sensitive subjects.
The level of quality of web pages
offering medical information varies
and evaluation of quality is difficult.
It may also be difficult to draw a
line between drug information and
drug marketing. It remains unclear
at present how consumers choose
and evaluate the medical informa-
tion they find on the Internet and
what effect the information has on
their choices (6). Nevertheless, the
role of the Internet as the source of
medical information and the benefits
offered by and disadvantages at-
tached to it are the subject of several
extensive surveys being carried out
in Europe at present.
According to this survey, the
amount of medical information that
Finnish consumers search for on the
Internet is great and varied. Further-
more, they also value highly the in-
formation they receive. Pages of ill-
ness related marketing appear to en-
courage the consumers to seek help
for their symptoms and especially to
make an appointment with a doctor
to discuss them. Companies in-
volved in marketing by symptoms
have a high degree of responsibility:
the contents of the pages should not
have marketing characteristics, but
the information offered should in-
stead be varied, of good quality and
correct.
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Fig.  2.  Sources from which the respondents aimed at  gett ing addit ional
information
Fig.  1 .  Areas of  interest  in  which the respondents were seeking infor-
mation on the web pages of  i l lness related marketing
